Holen Sie sich die Stockscreener-App
28.41
0.89%
0.25
Handel nachbörslich:
28.50
0.09
+0.32%
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
(AGIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
What Wall Street predicts for Agios Pharmaceuticals Inc. stock priceJuly 2025 Patterns & AI Forecasted Entry and Exit Points - ulpravda.ru
What RSI levels show for Agios Pharmaceuticals Inc. (8AP) stockEarnings Recap Summary & Detailed Earnings Play Strategies - ulpravda.ru
Market Review: How Agios Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Drop Watch & Technical Buy Zone Confirmation - ulpravda.ru
Why Agios Pharmaceuticals Inc. stock is seen as undervalued2025 Trade Ideas & High Return Trade Opportunity Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Price Swings & Stepwise Trade Signal Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock performs after earnings2025 Market WrapUp & Verified High Yield Trade Plans - ulpravda.ru
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? - Yahoo Finance
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock - Investing.com
Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Nigeria
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) to $25 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Agios Pharmaceuticals, Inc. (AGIO): Investor Outlook Highlights A Potential 33% Upside - DirectorsTalk Interviews
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
How FDA Approval of First-in-Class Thalassemia Anemia Drug AQVESME Could Impact Agios Pharmaceuticals (AGIO) Investors - Sahm
Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares - MarketBeat
Agios pharma chief legal officer Burns sells $79k in stock - Investing.com Canada
Agios pharma chief medical officer Gheuens sells $79k in stock - Investing.com Canada
Agios Pharmaceuticals CEO Goff sells $506,663 in stock - Investing.com
Jones Cecilia, Agios Pharmaceuticals CFO, sells $79k in stock By Investing.com - Investing.com UK
Agios Pharma shares jump 16% as US FDA expands approval for blood disorder drug - MSN
Momentum Indicator Shows Bearish Divergence in Sylvan Plyboard India LimitedRisk-Reward Ratio Analysis & Stay Ahead With Daily Market Discussions - earlytimes.in
How Agios Pharmaceuticals Inc. stock valuations compare to rivalsStock Correlation Metrics & Free Superior Profit Margins - bollywoodhelpline.com
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - MSN
Geopolitics Watch: Is Agios Pharmaceuticals Inc 8AP stock attractive post correctionLayoff News & Low Risk Entry Point Tips - moha.gov.vn
FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3%Should You Sell? - MarketBeat
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price T - GuruFocus
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Yahoo Finance
BofA Securities raises Agios Pharma stock price target on FDA approval - Investing.com India
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK - Finviz
B of A Securities Maintains Agios Pharmaceuticals (AGIO) Buy Recommendation - MSN
Agios Pharmaceuticals price target raised to $34 from $32 at BofA - Yahoo Finance
Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate - Trefis
Agios Pharma shares jump as US FDA expands approval for blood disorder drug - wibqam.com
Why Agios Pharmaceuticals (AGIO) Is Up 14.6% After First-in-Class Thalassemia Drug AQVESME Wins FDA Approval - Sahm
FDA approves Agios Pharmaceuticals’ Aqvesme in anemia patients - MSN
Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright - Investing.com India
Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha
Here's Why Shares in Agios Pharmaceuticals Popped Today - AOL.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Here's Why Shares in Agios Pharmaceuticals Popped Today - The Motley Fool
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta ThalassemiaSlideshow (NASDAQ:AGIO) 2025-12-24 - Seeking Alpha
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):